Download MendeleyA novel phosphotyrosine mimetic 4'-carboxymethyloxy-3'-phosphonophenylalanine (Cpp): exploitation in the design of nonpeptide inhibitors of pp60(Src) SH2 domain.
Kawahata, N., Yang, M.G., Luke, G.P., Shakespeare, W.C., Sundaramoorthi, R., Wang, Y., Johnson, D., Merry, T., Violette, S., Guan, W., Bartlett, C., Smith, J., Hatada, M., Lu, X., Dalgarno, D.C., Eyermann, C.J., Bohacek, R.S., Sawyer, T.K.(2001) Bioorg Med Chem Lett 11: 2319-2323
- PubMed: 11527723
- DOI: https://doi.org/10.1016/s0960-894x(01)00446-2
- Primary Citation of Related Structures:
1IJR - PubMed Abstract:
The novel phosphotyrosine (pTyr) mimetic 4'-carboxymethyloxy-3'-phosphonophenylalanine (Cpp) has been designed and incorporated into a series of nonpeptide inhibitors of the SH2 domain of pp60(c-Src) (Src) tyrosine kinase. A 2.2 A X-ray crystal structure of 1a bound to a mutant form of Lck SH2 domain provides insight regarding the structure-activity relationships and supports the design concept of this new pTyr mimetic.
Organizational Affiliation:
ARIAD Pharmaceuticals, Inc., Cambridge, MA 02139-4234, USA.
